[go: up one dir, main page]

MX2011011206A - Composiciones topicas estables para derivados de 1,2,4-tiadiazol. - Google Patents

Composiciones topicas estables para derivados de 1,2,4-tiadiazol.

Info

Publication number
MX2011011206A
MX2011011206A MX2011011206A MX2011011206A MX2011011206A MX 2011011206 A MX2011011206 A MX 2011011206A MX 2011011206 A MX2011011206 A MX 2011011206A MX 2011011206 A MX2011011206 A MX 2011011206A MX 2011011206 A MX2011011206 A MX 2011011206A
Authority
MX
Mexico
Prior art keywords
stable
stable topical
topical composition
composition
thiadiazole derivatives
Prior art date
Application number
MX2011011206A
Other languages
English (en)
Inventor
Chengji Cui
Shirley Mei-King Ng
George Wong
Mohammed Yusuf
Fa Zhang
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of MX2011011206A publication Critical patent/MX2011011206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud proporciona una composición tópica estable que comprende un compuesto de derivados de 1,2,4-tiadiazola y los derivados de tiourea relacionados; la composición tópica estable puede estar presente en varias formas, incluyendo gel acuoso, crema y emulsión; la composición tópica estable puede almacenarse en condiciones refrigeradas o a temperatura ambiente por un tiempo razonable; la presente solicitud también proporciona un método de tratamiento de trastornos dermatológicos mediados por un receptor de melanocortina que utiliza la composición tópica estable; la composición estable puede suministrarse utilizando un dispositivo de una cámara o de doble cámara; también se proporciona un método de preparación y suministro de la composición estable.
MX2011011206A 2009-04-24 2010-04-23 Composiciones topicas estables para derivados de 1,2,4-tiadiazol. MX2011011206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17252609P 2009-04-24 2009-04-24
PCT/US2010/032186 WO2010124175A1 (en) 2009-04-24 2010-04-23 Stable topical compositions for 1,2,4-thiadiazole derivatives

Publications (1)

Publication Number Publication Date
MX2011011206A true MX2011011206A (es) 2012-02-28

Family

ID=42237364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011206A MX2011011206A (es) 2009-04-24 2010-04-23 Composiciones topicas estables para derivados de 1,2,4-tiadiazol.

Country Status (15)

Country Link
US (3) US20100273838A1 (es)
EP (1) EP2421521A1 (es)
JP (1) JP2012524814A (es)
KR (1) KR20120044287A (es)
CN (1) CN102458384A (es)
AU (1) AU2010238710A1 (es)
BR (1) BRPI1013853A2 (es)
CA (1) CA2759730A1 (es)
CL (1) CL2011002648A1 (es)
MX (1) MX2011011206A (es)
NZ (1) NZ596138A (es)
RU (1) RU2011147592A (es)
SG (2) SG175773A1 (es)
WO (1) WO2010124175A1 (es)
ZA (1) ZA201108618B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DK2278962T3 (en) 2008-02-21 2014-03-10 Janssen Pharmaceutica Nv Methods for the treatment of dermatological disorders
EP2523660A4 (en) * 2010-01-14 2013-07-10 Nuvo Res Inc FORMATION OF SOLID FORMS OF LOCAL ANESTHESIA FORMULATIONS FOR FIGHTING PAIN
US9132291B2 (en) 2010-10-05 2015-09-15 Dfb Technology, Ltd. Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
FR2967054B1 (fr) * 2010-11-05 2013-01-25 Lea Lab Systeme conservateur
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20140023979A1 (en) * 2012-07-18 2014-01-23 Maha Mohamed Fouad Mounir Regeneration of ameloblast cells and dental enamel in vivo
WO2014080283A2 (en) * 2012-11-21 2014-05-30 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
JP6480847B2 (ja) * 2014-10-15 2019-03-13 第一三共ヘルスケア株式会社 ロキソプロフェン含有外用剤組成物
TW201630606A (zh) * 2015-01-21 2016-09-01 諾華公司 包含局部藥物之蓋崙（ｇａｌｅｎｉｃ）調配物
WO2017103719A1 (en) * 2015-12-15 2017-06-22 Therapeutics Inc. Halobetasol foam composition and method of use thereof
KR101966673B1 (ko) * 2016-11-21 2019-04-08 에이디인터내셔날㈜ 항균탈취 조성물
CN109400724B (zh) * 2018-11-05 2021-04-02 中国科学院烟台海岸带研究所 一种含噻二唑脲类乙酰化淀粉及其制备方法和应用
KR20200053746A (ko) * 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
BR112022012974A2 (pt) * 2020-01-08 2022-09-13 Principia Biopharma Inc Composições farmacêuticas tópicas que compreendem 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-eno-nitrila
CN114292689B (zh) * 2021-12-07 2023-03-31 广州崃克保新材料科技有限公司 一种脱模剂组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103194A1 (en) * 1997-04-30 2002-08-01 Anabella Villalobos Novel muscarinic receptor agonists
EP0805153B1 (en) * 1996-04-30 2001-11-14 Pfizer Inc. Novel muscarinic receptor agonists
EP1076648B1 (de) * 1998-04-29 2006-07-12 MERCK PATENT GmbH Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
BR0214024A (pt) * 2001-11-08 2004-12-07 Ortho Mcneil Pharm Inc Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US7435429B2 (en) * 2002-02-07 2008-10-14 Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
DK2278962T3 (en) * 2008-02-21 2014-03-10 Janssen Pharmaceutica Nv Methods for the treatment of dermatological disorders

Also Published As

Publication number Publication date
JP2012524814A (ja) 2012-10-18
ZA201108618B (en) 2013-05-29
NZ596138A (en) 2013-11-29
US20130210868A1 (en) 2013-08-15
AU2010238710A1 (en) 2011-11-17
EP2421521A1 (en) 2012-02-29
CL2011002648A1 (es) 2012-07-20
SG10201401006QA (en) 2014-10-30
US20100273838A1 (en) 2010-10-28
KR20120044287A (ko) 2012-05-07
WO2010124175A1 (en) 2010-10-28
BRPI1013853A2 (pt) 2019-09-24
RU2011147592A (ru) 2013-05-27
US20130203823A1 (en) 2013-08-08
CN102458384A (zh) 2012-05-16
CA2759730A1 (en) 2010-10-28
SG175773A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
MX2011011206A (es) Composiciones topicas estables para derivados de 1,2,4-tiadiazol.
PH12013500081B1 (en) Aqueous composition comprising bromhexine
WO2007137066A3 (en) HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
MY160703A (en) Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
WO2006107673A3 (en) Method of regulating mammalian keratinous tissue
PT2210588E (pt) Composição expansível, essencialmente isenta de ingredientes farmaceuticamente activos para o tratamento da pele humana
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina&#34;
WO2014195966A3 (en) Amorphous form of canagliflozin and process for preparing thereof
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
PH12013502215A1 (en) Beautiful-skin-promoting agent and use thereof
MX2010004373A (es) Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos.
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
UA105920C2 (uk) ПОХІДНІ СПОЛУК СТЕРОЇДАЛ[3,2-с]ПІРАЗОЛУ З ГЛЮКОКОРТИКОЇДНОЮ АКТИВНІСТЮ
WO2008112596A3 (en) Implantable device with bioabsorbable layer, kit and method for use therewith, and apparatus for preparing same
MX2009003060A (es) Emulsion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal